Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Moderna Gains FDA Authorization for Its Coronavirus Vaccine

By Brian Orelli, PhD - Dec 18, 2020 at 9:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A second vaccine is available in the U.S.

The Food and Drug Administration authorized a second coronavirus vaccine on Friday. The emergency use authorization (EUA) for Moderna's ( MRNA -7.53% ) mRNA-1273 comes just a day after the agency's advisory committee unanimously recommend authorizing the vaccine and a week after Pfizer ( PFE 2.45% ) and BioNTech ( BNTX -6.63% ) received an EUA for their coronavirus vaccine, BNT162b2.

Moderna plans to deliver approximately 20 million doses of the vaccine by the end of the month.

Hand holding a syringe in front of a shoulder

Image source: Getty Images.

The EUAs allow the drugmakers to sell their vaccines in the U.S. as long as the pandemic emergency continues. Both Pfizer and Moderna have said they plan to apply for full approval next year once they have the additional safety data the FDA is requiring for a full approval.

Moderna's vaccine has a few advantages over Pfizer and BioNTech's vaccine, including easier storage requirements. In their respective clinical trials, mRNA-1273 also appeared to provide better protection from severe COVID-19. Of the 196 COVID-19 cases in the clinical trial, none of the participants who got mRNA-1273 developed severe COVID-19, while 30 of the cases in the placebo group were classified as severe.

But Pfizer and BioNTech's BNT162b2 does have some advantages in other areas. The vaccine is authorized for people 16 years and older, while the lower age for Moderna's mRNA-1273 is 18 years old. The side effect profile, especially after the second dose, also appears to be milder for BNT162b2 compared to mRNA-1273.

Of course, in the short-term, there won't much of a competition between the two vaccines since neither group will be able to manufacture enough vaccine to meet the demand for the foreseeable future.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$340.77 (-7.53%) $-27.74
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.69 (2.45%) $1.28
BioNTech SE Stock Quote
BioNTech SE
BNTX
$338.50 (-6.63%) $-24.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.